Delayed Danish state Covid vaccine to be trialled on humans in 2022

National Danish infectious disease research organization Statens Serum Institut has found a manufacturer for its in-house Covid-19 vaccine, moving it closer to testing the candidate on human subjects following a series of delays.

Seruminstituttets chefvirolog Anders Fomsgaard siger, at man er tæt på | Photo: Tobias Nicolai/IND

BY RITZAU, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Denmark's second coronavirus vaccine, Covaxix, which is being developed by National Danish infectious disease research organization Statens Serum Insitut (SSI), has come closer to being tested on humans in phase I and II trials in 2022 after a string of delays.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Bavarian Nordic CEO sees massive sales potential for Covid-19 vaccine after securing state aid
For subscribers
EU approves Danish plan to put EUR 108m behind Bavarian Nordic's Covid-19 vaccine
For subscribers
Bavarian Nordic initiates phase II trial for Covid-19 vaccine
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

For subscribers

Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech